GlassScriptPhysician profile
Shaun M Moon
NPI 1942614953
$4,036.31
in general payments reported to CMS, 2019-2025
40 companies · $757 in 2025
The $757 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $303 · 2021: $217 · 2022: $441 · 2023: $791 · 2024: $629 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $602.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $454.56 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $307.69 | 2019-2025 | |
| Astellas Pharma US INC | $246.56 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $191.78 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $168.17 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $155.30 | 2020-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $145.26 | 2019-2025 | Mounjaro, Zepbound |
| Seqirus USA INC | $123.11 | 2023-2025 | Flucelvax Quadrivalent, Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $117.07 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $103.80 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.31 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.66 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $77.30 | 2019-2025 | Farxiga, Airsupra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.